129 related articles for article (PubMed ID: 16937357)
81. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
82. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection.
Lin HH; Ke HL; Wu WJ; Lee YH; Chang LL
Urol Oncol; 2012; 30(2):177-81. PubMed ID: 20800513
[TBL] [Abstract][Full Text] [Related]
83. Frequent silencing of RASSF1A by DNA methylation in thymic neuroendocrine tumours.
Kajiura K; Takizawa H; Morimoto Y; Masuda K; Tsuboi M; Kishibuchi R; Wusiman N; Sawada T; Kawakita N; Toba H; Yoshida M; Kawakami Y; Naruto T; Imoto I; Tangoku A; Kondo K
Lung Cancer; 2017 Sep; 111():116-123. PubMed ID: 28838380
[TBL] [Abstract][Full Text] [Related]
84. RASSF1A gene promoter methylation in esophageal cancer specimens.
Yamaguchi S; Kato H; Miyazaki T; Sohda M; Kimura H; Ide M; Asao T; Kuwano H
Dis Esophagus; 2005; 18(4):253-6. PubMed ID: 16128782
[TBL] [Abstract][Full Text] [Related]
85. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
86. Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours.
Ahmad F; Surve P; Natarajan S; Patil A; Pol S; Patole K; Das BR
Cancer Genet; 2020 Feb; 241():42-50. PubMed ID: 31653608
[TBL] [Abstract][Full Text] [Related]
87. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors.
López-Terrada D; Gunaratne PH; Adesina AM; Pulliam J; Hoang DM; Nguyen Y; Mistretta TA; Margolin J; Finegold MJ
Hum Pathol; 2009 Jun; 40(6):783-94. PubMed ID: 19200579
[TBL] [Abstract][Full Text] [Related]
88. Adiposity and age are statistically related to enhanced RASSF1A tumor suppressor gene promoter methylation in normal autopsy kidney tissue.
Peters I; Vaske B; Albrecht K; Kuczyk MA; Jonas U; Serth J
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2526-32. PubMed ID: 18086755
[TBL] [Abstract][Full Text] [Related]
89. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors.
Chang Q; Pang JC; Li KK; Poon WS; Zhou L; Ng HK
Hum Pathol; 2005 Dec; 36(12):1265-72. PubMed ID: 16311119
[TBL] [Abstract][Full Text] [Related]
90. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
91. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer.
Cheng YY; Yu J; Wong YP; Man EP; To KF; Jin VX; Li J; Tao Q; Sung JJ; Chan FK; Leung WK
Br J Cancer; 2007 Oct; 97(7):895-901. PubMed ID: 17848950
[TBL] [Abstract][Full Text] [Related]
92. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
93. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.
Lusher ME; Lindsey JC; Latif F; Pearson AD; Ellison DW; Clifford SC
Cancer Res; 2002 Oct; 62(20):5906-11. PubMed ID: 12384556
[TBL] [Abstract][Full Text] [Related]
94. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
95. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
[TBL] [Abstract][Full Text] [Related]
96. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
97. The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
Jiang Y; Cui L; Chen WD; Shen SH; Ding LD
PLoS One; 2012; 7(5):e36780. PubMed ID: 22615811
[TBL] [Abstract][Full Text] [Related]
98. Clinical utility of RASSF1A methylation in human malignancies.
Grawenda AM; O'Neill E
Br J Cancer; 2015 Jul; 113(3):372-81. PubMed ID: 26158424
[TBL] [Abstract][Full Text] [Related]
99. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.
Wang HL; Zhang Y; Liu P; Zhou PY
Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684
[TBL] [Abstract][Full Text] [Related]
100. Genetic and epigenetic basis of hepatoblastoma diversity.
Nagae G; Yamamoto S; Fujita M; Fujita T; Nonaka A; Umeda T; Fukuda S; Tatsuno K; Maejima K; Hayashi A; Kurihara S; Kojima M; Hishiki T; Watanabe K; Ida K; Yano M; Hiyama Y; Tanaka Y; Inoue T; Ueda H; Nakagawa H; Aburatani H; Hiyama E
Nat Commun; 2021 Sep; 12(1):5423. PubMed ID: 34538872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
